Oculis (NASDAQ:OCS) Shares Gap Up – Here’s What Happened

Oculis Holding AG (NASDAQ:OCS)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $15.81, but opened at $16.49. Oculis shares last traded at $16.30, with a volume of 2,449 shares changing hands.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Oculis in a research note on Wednesday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $29.20.

Oculis Stock Performance

The company has a current ratio of 5.27, a quick ratio of 5.27 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $646.04 million, a price-to-earnings ratio of -8.96 and a beta of 0.30. The company has a 50-day moving average of $12.89 and a 200-day moving average of $12.20.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.13). The firm had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.28 million. Oculis had a negative net margin of 7,679.05% and a negative return on equity of 61.33%. On average, equities research analysts forecast that Oculis Holding AG will post -2.19 earnings per share for the current fiscal year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.